| NCT01004172 | Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases | |
| NCT01401959 | Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy | |
| NCT00404066 | Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | |
| NCT00134680 | Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC | |
| NCT00303108 | Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer | |
| NCT00401427 | HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer | |
| NCT00490646 | A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer | |
| NCT01423695 | Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer | |
| NCT01491737 | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer | |
| NCT00093145 | Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer | |
| NCT00548184 | Lapatinib and Trastuzumab With or Without Endocrine Therapy | |
| NCT00820872 | Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer | |
| NCT00003612 | Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer | |
| NCT01276041 | Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer | |
| NCT00258960 | Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | |
| NCT00238290 | Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer | |
| NCT02073487 | Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel | |
| NCT00971737 | Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer | |
| NCT00254592 | Neoadjuvant Treatment of Breast Cancer | |
| NCT00841828 | Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | |
| NCT01008150 | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | |
| NCT00912340 | Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer | |
| NCT00847171 | Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer | |
| NCT00266110 | Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | |
| NCT00428922 | Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients | |
| NCT01485926 | A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients. | |
| NCT01973660 | PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer | |
| NCT00944047 | Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression | |
| NCT01142778 | A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer | |
| NCT00617942 | Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer | |
| NCT00303992 | Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer | |
| NCT00201760 | Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer | |
| NCT00107393 | Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer | |
| NCT00148668 | Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer | |
| NCT00136539 | Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | |
| NCT00068341 | Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer | |
| NCT00093808 | Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer | |
| NCT00041067 | S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer | |
| NCT00019812 | Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 | |
| NCT00005635 | Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | |
| NCT00006381 | Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer | |
| NCT00006110 | Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer | |
| NCT00006104 | Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer | |
| NCT00004013 | Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer | |
| NCT00003992 | Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 | |
| NCT00003539 | Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer | |
| NCT02748213 | A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | |
| NCT01206881 | Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | |
| NCT01242449 | Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer | |
| NCT01367028 | A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer | |
| NCT01401166 | Patients' Preference of Herceptin (Trastuzumab) Subcutaneous Versus Intravenous Administration in HER2-positive Early Breast Cancer | |
| NCT01565083 | A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer | |
| NCT01674062 | A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer | |
| NCT00717405 | A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer. | |
| NCT00712881 | Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer | |
| NCT00670982 | Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer | |
| NCT00679341 | A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease | |
| NCT00629499 | Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer | |
| NCT00545688 | A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. | |
| NCT00532857 | Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab | |
| NCT00493649 | Adj TC + Herceptin Early Stage Breast Cancer | |
| NCT00475670 | A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer | |
| NCT00482391 | Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer | |
| NCT00976989 | A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer | |
| NCT00943410 | Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer | |
| NCT00885755 | A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer | |
| NCT00821886 | Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer | |
| NCT00811135 | A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer | |
| NCT00795899 | Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO) | |
| NCT00769470 | Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery | |
| NCT00392392 | Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer | |
| NCT00411788 | A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer | |
| NCT00444587 | A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. | |
| NCT00464646 | Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer | |
| NCT00429104 | Herceptin and GM-CSF for Metastatic Breast Cancer | |
| NCT00429247 | Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients | |
| NCT00301899 | Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab | |
| NCT00297596 | Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer | |
| NCT00364611 | Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer | |
| NCT00365365 | Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer | |
| NCT00379015 | Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer | |
| NCT00337649 | A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer. | |
| NCT00232479 | Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer | |
| NCT00182793 | Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer | |
| NCT00193089 | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer | |
| NCT00193076 | Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer | |
| NCT00193063 | Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer | |
| NCT00191451 | A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer | |